Literature DB >> 11713928

Inhibition of beta-catenin translocation in rodent colorectal tumors: a novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer.

W A Brown1, S A Skinner, D Vogiagis, P E O'Brien.   

Abstract

In a rodent colorectal cancer model, nonsteroidal antiinflammatory drugs reduce tumor mass by increasing the rate of tumor cell apoptosis and decreasing proliferation. We have examined beta-catenin as a potential target for these agents in colorectal cancer. Carcinogen-treated rats were treated for 23 weeks with a range of nonsteroidal antiinflammatory drugs. Control animals received vehicle alone. Intracellular beta-catenin was examined using immunohistochemistry. In tumors from untreated animals, staining was seen in the cytoplasm and nucleus (median 24% of nuclei). The frequency of nuclear beta-catenin staining correlated directly with the volume of tumor and inversely with the rate of apoptosis. In tumors from treatment groups, the cytoplasmic staining for beta-catenin was unchanged; however, nuclear staining was absent except in the celecoxib group, where it was reduced to a median of 14%. Colorectal tumors from animals treated with NSAIDs show reduced levels of nuclear beta-catenin immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713928     DOI: 10.1023/a:1012326525692

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  47 in total

1.  Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1.

Authors:  J Roose; G Huls; M van Beest; P Moerer; K van der Horn; R Goldschmeding; T Logtenberg; H Clevers
Journal:  Science       Date:  1999-09-17       Impact factor: 47.728

Review 2.  Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.

Authors:  J L Masferrer; P C Isakson; K Seibert
Journal:  Gastroenterol Clin North Am       Date:  1996-06       Impact factor: 3.806

3.  Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

Authors:  G A Kune; S Kune; L F Watson
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

4.  NSAIDs, Cox-2 inhibitors, and the gut.

Authors:  J R Vane
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

5.  The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.

Authors:  H C Crawford; B M Fingleton; L A Rudolph-Owen; K J Goss; B Rubinfeld; P Polakis; L M Matrisian
Journal:  Oncogene       Date:  1999-05-06       Impact factor: 9.867

6.  Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.

Authors:  C H Chiu; M F McEntee; J Whelan
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

7.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

8.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

Authors:  H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

9.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

Authors:  M Shtutman; J Zhurinsky; I Simcha; C Albanese; M D'Amico; R Pestell; A Ben-Ze'ev
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.

Authors:  R N DuBois; A Radhika; B S Reddy; A J Entingh
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  9 in total

1.  Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs.

Authors:  Desheng Lu; Howard B Cottam; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

2.  Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.

Authors:  Caihua Zhu; Ka-Wing Cheng; Nengtai Ouyang; Liqun Huang; Yu Sun; Panayiotis Constantinides; Basil Rigas
Journal:  Stem Cells       Date:  2012-10       Impact factor: 6.277

3.  Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.

Authors:  Gunnar Steinert; Claudia Oancea; Jessica Roos; Heike Hagemeyer; Thorsten Maier; Martin Ruthardt; Elena Puccetti
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

Review 4.  Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.

Authors:  Roya Tabatabai; Yuliya Linhares; David Bolos; Monica Mita; Alain Mita
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.864

5.  Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition.

Authors:  Bostjan Humar; Les McNoe; Anita Dunbier; Rosemary Heathcott; Antony W Braithwaite; Anthony E Reeve
Journal:  Biologics       Date:  2008-06

6.  Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin.

Authors:  Angelo Pietro Femia; Piero Dolara; Maddalena Salvadori; Giovanna Caderni
Journal:  BMC Cancer       Date:  2013-02-01       Impact factor: 4.430

7.  Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.

Authors:  E M J Boon; J J Keller; T A M Wormhoudt; F M Giardiello; G J A Offerhaus; R van der Neut; S T Pals
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

8.  Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells.

Authors:  S H Gardner; G Hawcroft; M A Hull
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

Review 9.  A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers.

Authors:  Kamal Ahmed; Holly V Shaw; Alexey Koval; Vladimir L Katanaev
Journal:  Cancers (Basel)       Date:  2016-07-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.